PL190777B1 - Związek bedący 2-{4-[4-(4,5-dichloro-2-metyloimidazol-1-ilo)butylo]-piperazyn-1-ylo}-5-fluoropirymidyną, sposób jego wytwarzania, zastosowanie związku oraz kompozycja farmaceutyczna zawierająca go - Google Patents
Związek bedący 2-{4-[4-(4,5-dichloro-2-metyloimidazol-1-ilo)butylo]-piperazyn-1-ylo}-5-fluoropirymidyną, sposób jego wytwarzania, zastosowanie związku oraz kompozycja farmaceutyczna zawierająca goInfo
- Publication number
- PL190777B1 PL190777B1 PL337113A PL33711398A PL190777B1 PL 190777 B1 PL190777 B1 PL 190777B1 PL 337113 A PL337113 A PL 337113A PL 33711398 A PL33711398 A PL 33711398A PL 190777 B1 PL190777 B1 PL 190777B1
- Authority
- PL
- Poland
- Prior art keywords
- dichloro
- reaction
- piperazin
- methylimidazol
- butyl
- Prior art date
Links
- GHLXRTOLSFXWOA-UHFFFAOYSA-N 2-[4-[4-(4,5-dichloro-2-methylimidazol-1-yl)butyl]piperazin-1-yl]-5-fluoropyrimidine Chemical compound CC1=NC(Cl)=C(Cl)N1CCCCN1CCN(C=2N=CC(F)=CN=2)CC1 GHLXRTOLSFXWOA-UHFFFAOYSA-N 0.000 title claims abstract description 9
- 239000003814 drug Substances 0.000 title claims description 8
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 229940079593 drug Drugs 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 13
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- 206010028813 Nausea Diseases 0.000 claims description 8
- 201000003152 motion sickness Diseases 0.000 claims description 7
- 230000008693 nausea Effects 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 230000027119 gastric acid secretion Effects 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- GCHGPDZLNPVQFH-UHFFFAOYSA-N 2-[4-[4-(4,5-dichloro-2-methylimidazol-1-yl)butyl]piperazin-1-yl]-5-fluoropyrimidine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CC1=NC(Cl)=C(Cl)N1CCCCN1CCN(C=2N=CC(F)=CN=2)CC1 GCHGPDZLNPVQFH-UHFFFAOYSA-N 0.000 claims description 3
- JLTAEIXLCAXZCQ-UHFFFAOYSA-N 4,5-dichloro-1-(4-chlorobutyl)-2-methylimidazole Chemical compound CC1=NC(Cl)=C(Cl)N1CCCCCl JLTAEIXLCAXZCQ-UHFFFAOYSA-N 0.000 claims description 3
- ZWRYWVBALYOSPQ-UHFFFAOYSA-N 4,5-dichloro-2-methyl-1h-imidazole Chemical compound CC1=NC(Cl)=C(Cl)N1 ZWRYWVBALYOSPQ-UHFFFAOYSA-N 0.000 claims description 3
- GXXFECFLKWGTNP-UHFFFAOYSA-N 5-fluoro-2-piperazin-1-ylpyrimidine Chemical compound N1=CC(F)=CN=C1N1CCNCC1 GXXFECFLKWGTNP-UHFFFAOYSA-N 0.000 claims description 3
- GTYPNJSDALPKIM-UHFFFAOYSA-N 8-(5-fluoropyrimidin-2-yl)-8-aza-5-azoniaspiro[4.5]decane Chemical compound N1=CC(F)=CN=C1N1CC[N+]2(CCCC2)CC1 GTYPNJSDALPKIM-UHFFFAOYSA-N 0.000 claims description 3
- 239000000010 aprotic solvent Substances 0.000 claims description 3
- -1 4,5-dichloro-2-methylimidazol-1-yl Chemical group 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 206010033664 Panic attack Diseases 0.000 claims description 2
- 208000012886 Vertigo Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000019906 panic disease Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 201000002859 sleep apnea Diseases 0.000 claims description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 231100000889 vertigo Toxicity 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 238000009835 boiling Methods 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 206010047700 Vomiting Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 230000001430 anti-depressive effect Effects 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 229910000365 copper sulfate Inorganic materials 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 241000428199 Mustelinae Species 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000288722 Suncus murinus Species 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
- 244000171897 Acacia nilotica subsp nilotica Species 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102000017911 HTR1A Human genes 0.000 description 1
- 101150015707 HTR1A gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920003082 Povidone K 90 Polymers 0.000 description 1
- 241000288726 Soricidae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000035045 associative learning Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- BYNVYIUJKRRNNC-UHFFFAOYSA-N docosanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCCCCCC(O)=O BYNVYIUJKRRNNC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000000586 effect on nausea Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 150000002460 imidazoles Chemical group 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9706738A FR2763950B1 (fr) | 1997-06-02 | 1997-06-02 | 2- {4- [4-(4,5-dichloro-2-methylimidazol-1-yl)butyl] -1- piperazinyl }-5-fluoropyrimidine, sa preparation et son utilisation therapeutique |
| PCT/EP1998/003190 WO1998055476A1 (fr) | 1997-06-02 | 1998-05-28 | 2-{4-[4-(4,5-dichloro-2- methylimidazol-1-yl)butyl] -1-piperazinyl}-5-fluoropyrimidine, sa preparation et son utilisation therapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL337113A1 PL337113A1 (en) | 2000-07-31 |
| PL190777B1 true PL190777B1 (pl) | 2006-01-31 |
Family
ID=9507480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL337113A PL190777B1 (pl) | 1997-06-02 | 1998-05-28 | Związek bedący 2-{4-[4-(4,5-dichloro-2-metyloimidazol-1-ilo)butylo]-piperazyn-1-ylo}-5-fluoropirymidyną, sposób jego wytwarzania, zastosowanie związku oraz kompozycja farmaceutyczna zawierająca go |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US6303608B1 (fr) |
| EP (1) | EP1007522B1 (fr) |
| JP (1) | JP4344890B2 (fr) |
| KR (1) | KR100556559B1 (fr) |
| CN (1) | CN1094491C (fr) |
| AT (1) | ATE228126T1 (fr) |
| AU (1) | AU732722B2 (fr) |
| BR (1) | BR9810240A (fr) |
| CA (1) | CA2292746A1 (fr) |
| DE (1) | DE69809564T2 (fr) |
| DK (1) | DK1007522T3 (fr) |
| ES (1) | ES2149691B1 (fr) |
| FR (1) | FR2763950B1 (fr) |
| HU (1) | HUP0002905A3 (fr) |
| IL (1) | IL133216A0 (fr) |
| NO (1) | NO318757B1 (fr) |
| NZ (1) | NZ501566A (fr) |
| PL (1) | PL190777B1 (fr) |
| PT (1) | PT1007522E (fr) |
| RU (1) | RU2191184C2 (fr) |
| TR (1) | TR199903001T2 (fr) |
| WO (1) | WO1998055476A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101152658B1 (ko) * | 2009-04-30 | 2012-06-18 | 한국과학기술연구원 | 세로토닌 5-ｈｔ6 길항 활성 효과를 갖는 피페라진 화합물 함유 조성물 |
| RU2660583C1 (ru) * | 2017-08-15 | 2018-07-06 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Применение буспирона для лечения функционального головокружения |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2642759B1 (fr) * | 1989-02-09 | 1991-05-17 | Laboratorios Esteve Sa | Derives de pyrimidyl-piperazinyl-alkyl azoles avec activite anxiolytique et/ou tranquillisante |
| FR2672052B1 (fr) | 1991-01-28 | 1995-05-24 | Esteve Labor Dr | Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments. |
| FR2673628B1 (fr) * | 1991-03-07 | 1993-07-09 | Esteve Labor Dr | Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles. |
| FR2712808B1 (fr) * | 1993-11-25 | 1996-02-16 | Esteve Labor Dr | Utilisation des dérivés de 1-{4-[4-aryl(ou hétéroaryl)-1-pipérazinyl]-butyl}-1-H-azole pour la préparation de médicaments destinés au traitement des troubles de la sécrétion gastrique . |
| FR2742052B1 (fr) * | 1995-12-12 | 1998-04-10 | Esteve Labor Dr | Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports |
-
1997
- 1997-06-02 FR FR9706738A patent/FR2763950B1/fr not_active Expired - Fee Related
-
1998
- 1998-05-28 KR KR1019997011267A patent/KR100556559B1/ko not_active IP Right Cessation
- 1998-05-28 EP EP98967138A patent/EP1007522B1/fr not_active Expired - Lifetime
- 1998-05-28 IL IL13321698A patent/IL133216A0/xx not_active IP Right Cessation
- 1998-05-28 TR TR1999/03001T patent/TR199903001T2/xx unknown
- 1998-05-28 HU HU0002905A patent/HUP0002905A3/hu unknown
- 1998-05-28 BR BR9810240-0A patent/BR9810240A/pt not_active Application Discontinuation
- 1998-05-28 CA CA002292746A patent/CA2292746A1/fr not_active Abandoned
- 1998-05-28 AU AU79170/98A patent/AU732722B2/en not_active Ceased
- 1998-05-28 JP JP50144499A patent/JP4344890B2/ja not_active Expired - Fee Related
- 1998-05-28 WO PCT/EP1998/003190 patent/WO1998055476A1/fr active IP Right Grant
- 1998-05-28 US US09/445,081 patent/US6303608B1/en not_active Expired - Fee Related
- 1998-05-28 PL PL337113A patent/PL190777B1/pl unknown
- 1998-05-28 AT AT98967138T patent/ATE228126T1/de not_active IP Right Cessation
- 1998-05-28 DE DE69809564T patent/DE69809564T2/de not_active Expired - Lifetime
- 1998-05-28 DK DK98967138T patent/DK1007522T3/da active
- 1998-05-28 RU RU2000100371/04A patent/RU2191184C2/ru not_active IP Right Cessation
- 1998-05-28 CN CN98806845A patent/CN1094491C/zh not_active Expired - Fee Related
- 1998-05-28 NZ NZ501566A patent/NZ501566A/en unknown
- 1998-05-28 PT PT98967138T patent/PT1007522E/pt unknown
- 1998-05-29 ES ES009801201A patent/ES2149691B1/es not_active Expired - Fee Related
-
1999
- 1999-12-01 NO NO19995894A patent/NO318757B1/no not_active Application Discontinuation
-
2001
- 2001-03-27 US US09/817,952 patent/US6346620B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NZ501566A (en) | 2001-06-29 |
| PT1007522E (pt) | 2003-04-30 |
| AU732722B2 (en) | 2001-04-26 |
| HUP0002905A3 (en) | 2002-01-28 |
| DK1007522T3 (da) | 2003-03-17 |
| FR2763950B1 (fr) | 2002-09-20 |
| BR9810240A (pt) | 2000-09-05 |
| DE69809564D1 (de) | 2003-01-02 |
| TR199903001T2 (xx) | 2000-07-21 |
| EP1007522B1 (fr) | 2002-11-20 |
| NO318757B1 (no) | 2005-05-02 |
| KR100556559B1 (ko) | 2006-03-06 |
| RU2191184C2 (ru) | 2002-10-20 |
| DE69809564T2 (de) | 2003-07-10 |
| CN1094491C (zh) | 2002-11-20 |
| FR2763950A1 (fr) | 1998-12-04 |
| NO995894D0 (no) | 1999-12-01 |
| WO1998055476A1 (fr) | 1998-12-10 |
| ES2149691B1 (es) | 2001-05-16 |
| ATE228126T1 (de) | 2002-12-15 |
| ES2149691A1 (es) | 2000-11-01 |
| AU7917098A (en) | 1998-12-21 |
| IL133216A0 (en) | 2001-03-19 |
| KR20010013274A (ko) | 2001-02-26 |
| HUP0002905A2 (hu) | 2001-06-28 |
| CA2292746A1 (fr) | 1998-12-10 |
| PL337113A1 (en) | 2000-07-31 |
| JP4344890B2 (ja) | 2009-10-14 |
| JP2002501539A (ja) | 2002-01-15 |
| CN1261888A (zh) | 2000-08-02 |
| US6346620B1 (en) | 2002-02-12 |
| EP1007522A1 (fr) | 2000-06-14 |
| US6303608B1 (en) | 2001-10-16 |
| NO995894L (no) | 2000-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4616025A (en) | Thiazolidine derivatives, process for the preparation and pharmaceutical compositions thereof | |
| CS247073B2 (en) | Production method of 2-substituted 4-amino-6,7-dimethoxyghinolins | |
| IL228630A (en) | Compounds for the treatment of metabolic syndrome and intermediates for the synthesis of these compounds | |
| CN115304590B (zh) | 2h-苯并三氮唑衍生物及其制备方法及含有它们的药物组合物 | |
| EA015745B1 (ru) | Соединения, проявляющие активность в отношении св | |
| JPH10231297A (ja) | 新規なアデニン−１−ｎ−オキシド誘導体およびその医薬用途 | |
| TW406083B (en) | Novel piperazine derivatives | |
| FR2489823A1 (fr) | Nouvelles n-((4-(3-pyridyle substitue en position 3)-piperazino)alkyl)azaspirodecanediones, leur procede de preparation et medicament les contenant | |
| JP2959598B2 (ja) | 光学活性なチエノトリアゾロジアゼピン化合物 | |
| JPS59137469A (ja) | 複素環式化合物，その製法およびそれらを含有する中枢神経系薬物 | |
| JPH02134368A (ja) | 新規なピリジル‐およびピリミジル誘導体 | |
| JPH02178263A (ja) | アザアズレン誘導体、その製造法およびそれを有効成分とする抗アレルギー剤および抗炎症剤 | |
| WO1997005129A1 (fr) | (r)-5-bromo-n-(1-ethyl-4-methylhexahydro-1h-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridine-carboxamide, son procede d'obtention et medicament le contenant | |
| JPS58146569A (ja) | イミダゾリジン誘導体 | |
| BG104151A (bg) | 3-ЗАМЕСТЕНИ 3,4,5,7-ТЕТРАХИДРОПИРОЛО [3,4,:4,5] ТИЕНО [2,39г] ПИРИМИДИНОВИ ПРОИЗВОДНИ, ТЯХНОТО ПОЛУЧАВАНЕ И ИЗПОЛЗВАНЕ | |
| PL190777B1 (pl) | Związek bedący 2-{4-[4-(4,5-dichloro-2-metyloimidazol-1-ilo)butylo]-piperazyn-1-ylo}-5-fluoropirymidyną, sposób jego wytwarzania, zastosowanie związku oraz kompozycja farmaceutyczna zawierająca go | |
| JPH04225917A (ja) | 記憶増強剤として有用な５−アリ−ル−４−アルキル−３ｈ−１，２，４−トリアゾール−３−チオン類 | |
| JPS60501207A (ja) | 化合物 | |
| JPH04500506A (ja) | Ａｃａｔ酵素をブロックするのに有効な二価リガンド類 | |
| CN100588398C (zh) | 用于治疗中枢神经系统紊乱的3-吲哚基丙酮酸的烯醇互变体基本纯的固体形式 | |
| JPH02124889A (ja) | イミダゾピラゾール誘導体 | |
| EP4079306A1 (fr) | Agent thérapeutique contenant un composé de pyrimidine en tant que principe actif | |
| AU759274B2 (en) | 2-(4-(4-(4,5-dichloro-2-methylimidazol-1-YL) butyl)-1-piperazinyl)-5-fluoropyrimidine, its preparation and its therapeutic use | |
| JPS6130588A (ja) | ベンゾ〔ｃ〕〔１，８〕ナフチリジン、その製造方法及びその使用、並びにこれらの化合物を含有する調製剤 | |
| WO2010041983A1 (fr) | 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines substituées, antagonistes des récepteurs 5-ht6 de sérotonine, procédés de fabrication et d'utilisation |